EP1709008A1 - Salts of hmg-coa reductase inhibitors and use thereof - Google Patents

Salts of hmg-coa reductase inhibitors and use thereof

Info

Publication number
EP1709008A1
EP1709008A1 EP05702276A EP05702276A EP1709008A1 EP 1709008 A1 EP1709008 A1 EP 1709008A1 EP 05702276 A EP05702276 A EP 05702276A EP 05702276 A EP05702276 A EP 05702276A EP 1709008 A1 EP1709008 A1 EP 1709008A1
Authority
EP
European Patent Office
Prior art keywords
rosuvastatin
formula
amine
optionally substituted
methylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05702276A
Other languages
German (de)
French (fr)
Inventor
Yatendra Kumar
Mohammad Rafeeq
Shantanu De
Swargam Sathyanarayana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of EP1709008A1 publication Critical patent/EP1709008A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Definitions

  • the present invention relates to salts of HMG CoA reductase inhibitors ⁇ and in particular, rosuvastatin amine salts and their use as intermediates in the preparation of rosuvastatin calcium.
  • Rosuvastatin is (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(l-methylethyl)-2-[methyl (methylsulfonyl)amino]-5- ⁇ yrimidinyl]-3,5-dihydroxy-6-heptenoic acid, shown as Formula II below, wherein R is a hydrogen atom.
  • Rosuvastatin or its pharmaceutically acceptable salts such as rosuvastatin calcium of Formula Ila (wherein R is calcium) and rosuvastatin magnesium of Formula lib (wherein R is magnesium) are antihypercholesterolemic drugs used in the treatment of atherosclerosis.
  • U.S. Patent No. RE 37,314 describes a process for the preparation of amorphous rosuvastatin calcium by dissolving the corresponding sodium salt in water, adding calcium chloride and collecting the resultant precipitate by filtration.
  • U.S. Patent No. 6,589,959 describes a process for the preparation of crystalline Form A of rosuvastatm by warming amorphous rosuvastatin calcium in a mixture of water and acetonitrile, cooling the resultant solution to ambient temperature, and then filtering the product which is then dried at 50°C under vacuum to give crystalline Form A of rosuvastatin calcium.
  • PCT patent application WO 01/60804 describes the preparation of crystalline rosuvastatin salts, namely, ammonium, methylammonium, ethylammonium, diethanolammonium, tri(hydroxymethyl)-methylammonium, benzylammonium, 4-methoxybenzylammonium, lithium and magnesium salts of crystalline rosuvastatin.
  • a process for preparation of rosuvastatin calcium from all these salts is also described in this patent application.
  • rosuvastatin which can be useful as intermediates in the preparation of pharmacologically acceptable salts of rosuvastatin, such as rosuvastatin calcium or rosuvastatin magnesium.
  • processes for the preparation of amine salts of rosuvastatin Also provided herein are processes of converting amine salts of rosuvastatin to pha ⁇ naceutically acceptable salts of rosuvastatin, such as calcium or magnesium.
  • pharmaceutical compositions comprising amine salts of rosuvastatin along with pharmaceutically acceptable excipients and/or carriers and methods of treatment of disease in which HMG-CoA reductase is implicated.
  • amine salts of rosuvastatin of Formula I refers to an amine salt or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula NRiR R wherein independently R 1; R 2 and R 3 are H, straight or branched chain C S alkyl or hydroxyalkyl, C 3 . 10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently R ? R 2 and R 3 can combine with each other to form a C 3 .
  • rosuvastatin of Formula II refers to the free acid of rosuvastatin, wherein R" is of Formula A and R is hydrogen or lactone form of compound of Formula II wherein R" is of Formula B.
  • R in Formula A is selected from metal ions capable of forming a salt or an amino acid residue and esters of rosuvastatin wherein R in Formula A is selected from optionally substituted - 5 alkyl, aryl, cycloalkyl and heterocyclic residues.
  • R in Formula A is selected from optionally substituted - 5 alkyl, aryl, cycloalkyl and heterocyclic residues.
  • the term also covers compounds of Formula II which can be present in crystalline, solvate, hydrate or amorphous form thereof.
  • Figure 1 is an X-ray diffraction pattern of the cyclohexyl ammonium salt of rosuvastatin, as prepared in Example 1.
  • Figure 2 is an X-ray diffraction pattern of the diisopropyl ammonium salt of rosuvastatin, as prepared in Example 2.
  • Figure 3 is an X-ray diffraction pattern of the isopropyl ammonium salt of rosuvastatin, as prepared in Example 3.
  • Figure 4 is an X-ray diffraction pattern of the dicyclohexyl ammonium salt of rosuvastatin, as prepared in Example 4.
  • Figure 5 is an X-ray diffraction pattern of the (S) (+)- D-methylbenzyl ammonium salt of rosuvastatm, as prepared in Example 5.
  • Figure 6 is an X-ray diffraction pattern of amorphous rosuvastatin calcium, as prepared in Example 6, step b).
  • Figure 7 is an X-ray diffraction pattern of crystalline rosuvastatin calcium, as prepared in Example 6, step c).
  • Figure 8 is an X-ray diffraction pattern of crystalline rosuvastatin magnesium, as prepared in Example 7.
  • amine salts of rosuvastatin of Formula I or solvate, hydrate, crystalline or amorphous forms thereof are provided, in which the amine residue has the formula NRiR R 3 wherein independently R 1 ⁇ R 2 and R 3 are H, straight or branched chain CM S alkyl or hydroxyalkyl, C 3 . 10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyL alkylcycloalkyl, or independently R l5 R 2 and R 3 can combine with each other to form a C 3 .
  • amine salts of rosuvastatin of Formula I having purity above 99% and diastereomeric impurity less than 0.5%, are also provided, for example, with purity more than 99.5% and diastereomeric impurity less than 0.25%, or with purity more than 99.75% and diastereomeric impurity less than 0.15%.
  • a process for preparation of amine salts of rosuvastatin of Formula I comprises: a) treating rosuvastatin of Formula II with an amine of Formula NR 1 R 2 R 3 wherein independently R l5 R 2 and R 3 are H, straight or branched chain C S alkyl or hydroxyalkyl, C 3 . 10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl or independently R l5 R 2 and R 3 can combine with each other to form a C 3 .
  • Rosuvastatin of Formula II can be dissolved or suspended in an organic solvent and to this mass can be added an amine of Formula NR ⁇ R 2 R 3 wherein R l5 R 2 and R 3 are as defined above at a temperature of from about -50 to about 100°C.
  • Amine salts of rosuvastatin of Formula I can precipitate from the reaction mass after stirring, which is then isolated, for example, by filtration.
  • the product can optionally be washed with a second organic solvent, in which compounds of Formula I are insoluble or very slightly soluble or sparingly soluble.
  • the product can then suitably be dried to get amine salts of rosuvastatin of Formula I in pure form, which can be further purified by crystallization or any other suitable method such as column chromatography.
  • the organic solvent used in the reaction is characterized by the fact that rosuvastatin of Formula II is very soluble or soluble in it whereas amine salts of rosuvastatin of Formula I are slightly soluble, very slightly soluble or insoluble in such solvent.
  • organic solvents are: esters such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate and isobutyl acetate; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone; and chlorinated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride and ethylene dichloride.
  • esters such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate and isobutyl acetate
  • ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone
  • chlorinated hydrocarbons such as methylene chloride, chloroform
  • the second organic solvent in which amine salts of rosuvastatin of Formula I are insoluble (10,000 and over parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) or very slightly soluble (form 1,000 to 10,000 parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) or sparingly soluble (from 30 to 100 parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) can be, for example, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane, diethyl ether, diisopropyl ether or mixtures thereof.
  • amine salts of rosuvastatin of Formula I or solvate, hydrate, crystalline or amorphous form thereof are provided, in which the amine residue has a Formula NRtRaRa (wherein independently R l5 R and R 3 are H, straight or branched chain C ⁇ -15 alkyl or hydroxyalkyl, C 3 - 10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently R ls R 2 and R 3 can combine with each other to form a C 3 .
  • Formula NRtRaRa wherein independently R l5 R and R 3 are H, straight or branched chain C ⁇ -15 alkyl or hydroxyalkyl, C 3 - 10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently R
  • Formula I are straightforward and simpler, as compared to processes described in, for example, PCT application WO 01/60804, with respect to the number and quantity of solvents used, reaction time and temperature, purity of product obtained and ease of isolating the final product.
  • the amine salts of Formula I as prepared by processes provided herein can be isolated as crystalline solids having a purity of at least above
  • processes for the preparation of amorphous or crystalline rosuvastatin calcium of Formula Ila from amine salt of Formula I are provided herein, wherein the process comprises: a) treating an amine salt of a compound of Formula I with an acid; b) optionally isolating rosuvastatm acid or a lactone thereof; c) adding a base and calcium ions; d) isolating amorphous rosuvastatin calcium; and e) optionally converting amorphous rosuvastatin calcium to crystalline rosuvastatin calcium.
  • Rosuvastatin amine salt of Formula I can be treated with an acid, at a pH of about 1 to about 4, to get rosuvastatin lactone, or at pH of about 4.5 to about 5, to get rosuvastatin acid.
  • the reaction can be carried out in the presence of a first organic solvent, optionally containing water, at a temperature of from about -10 to about 100°C. After completion of the reaction, the layers are separated and organic layer after washing with water and/or brine is concentrated completely under vacuum.
  • the residue obtained when the reaction pH is adjusted between 4.5 to 5 gives rosuvastatin acid as an oily liquid, which can then be dissolved in water and a first organic solvent, and treated with a base and calcium ions to give rosuvastatin calcium, which precipitates from the reaction mass as amorphous solid.
  • the mixture can be stirred at a temperature of about 40 to about 150°C for about 1 to about 50 hours to effect lactonization.
  • the second organic solvent can be removed from the reaction mass, for example, under vacuum, and the residue can be treated with second organic solvent to get the rosuvastatin lactone.
  • the residue can be as such taken in the next step without actually isolating the lactone.
  • the acid can be, for example, an inorganic mineral acid such as hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid; or an organic acid such as formic acid, acetic acid and the like.
  • the first organic solvent can be, for example, lower alkanols, ethers, esters, ketones, polar aprotic solvents, alkyl, aromatic or cycloalkyl hydrocarbons or mixtures thereof.
  • the lower alkanol can be, for example, methanol, ethanol, isopropanol, isobutanol, n-butanol and n-propanol.
  • the ethers can be, for example, tetrahydrofuran, 1,4-dioxane, diethyl ether and diisopropyl ether.
  • the esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and amyl acetate.
  • the ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone.
  • Polar aprotic solvents can be, for example, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N-methylpyrrolidone.
  • Alkyl, aromatic or cycloalkyl hydrocarbons can be, for example, toluene, benzene, xylene, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane or mixtures thereof.
  • the second organic solvent (characterized by the fact that rosuvastatin is insoluble or very slightly soluble or sparingly soluble in it) can be, for example, isopropanol, isobutanol, n-butanol, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane, diethyl ether, diisopropyl ether or mixtures thereof.
  • the lactone can then be dissolved in an organic solvent, optionally containing water, and treated with a base at a temperature of about 10 to about 70°C for about 1 to about 40 hours to effect hydrolysis of the lactone.
  • the reaction mass pH during the reaction can be adjusted to within the range of about 7.5 to about 11 using a base.
  • the solvent can then be removed and the residue can be taken up in water.
  • the aqueous solution can be washed with the first organic solvent as described earlier, and then treated with calcium ions, after which rosuvastatm calcium can precipitate from the aqueous solution as the amorphous solid.
  • the base can be, for example, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate or potassium bicarbonate.
  • the calcium ions can be generated by using a calcium compound which can be, for example, calcium chloride, calcium hydroxide, calcium carbonate, calcium acetate, calcium sulphate, calcium borate, calcium tartarate, calcium bromide or any other compound capable of generating calcium ions.
  • a process for the preparation of amorphous rosuvastatin calcium from amine salt rosuvastatm of Formula I is provided. The process comprises: a) treating an amine salt of rosuvastatin with a base and a calcium ions; and b) isolating amorphous rosuvastatin calcium from the reaction mass. Examples of base and calcium ion generating compounds are described in detail above.
  • the conversion can be easily carried out in presence of water, optionally containing an organic solvent.
  • the reaction temperature can be kept at about -5 to about 100°C.
  • the organic solvent can be, for example, lower alkanols, ethers, esters, ketones, polar aprotic solvents, alkyl or cycloalkyl hydrocarbons or mixtures thereof.
  • the lower alkanol can be, for example, methanol, ethanol, isopropanol, isobutanol, n-butanol and n- propanol.
  • the ethers can be, for example, tetrahydrofuran, 1,4-dioxane, diethyl ether and diisopropyl ether.
  • the esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and amyl acetate.
  • the ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone.
  • Polar aprotic solvents can be, for example, N,N- dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N- methylpyrrolidone.
  • Alkyl or cycloalkyl hydrocarbons can be, for example, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane or mixtures thereof.
  • the amorphous rosuvastatin calcium prepared as described above can have a purity of at least 99%, having less than 0.5% of diastereomeric impurity. It can then be crystallized by, for example, methods described in the US Patent No. 6,589,959, to get crystalline rosuvastatin calcium which can be further converted to amorphous rosuvastatin calcium by, for example, methods described in Indian application 1304/DEL/2003.
  • processes for the preparation of amorphous or crystalline rosuvastatin magnesium of Formula lib from amine salt of Formula I comprise: a) treating an amine salt of a compound of Formula I with an acid; b) optionally isolating rosuvastatin acid or a lactone thereof; c) adding a base and magnesium ions; d) isolating crystalline rosuvastatin magnesium; and e) optionally converting crystalline rosuvastatin magnesium to amorphous rosuvastatin magnesium.
  • the process is similar to that described earlier, however magnesium ions are used to prepare rosuvastatin magnesium instead of calcium ions.
  • the product obtained is crystalline rosuvastatin magnesium unlike the amorphous form obtained in case of rosuvastatin calcium.
  • the magnesium ions can be generated by using a magnesium compound such as, for example, magnesium chloride, magnesium hydroxide, magnesium carbonate, magnesium acetate, magnesium sulphate, magnesium borate, magnesium tartarate, magnesium bromide or any other compound capable of generating magnesium ions.
  • processes for the preparation of amorphous rosuvastatin magnesium from amine salt of rosuvastatin of Formula I are provided. The processes comprise: a) treating an amine salt of rosuvastatin with a base and a magnesium ions; and b) isolating the crystalline rosuvastatm magnesium from the reaction mass.
  • the process is similar to that described earlier, however, magnesium ions are used to prepare rosuvastatin magnesium instead of calcium ions.
  • the product obtained is crystalline rosuvastatin magnesium unlike the amorphous form obtained in case of rosuvastatin calcium.
  • the crystalline forms of rosuvastatin magnesium obtained above can be converted to amorphous rosuvastatin magnesium by, for example, processes described in hidian application 1304/DEL/2003.
  • highly pure rosuvastatin calcium or rosuvastatin magnesium in crystalline or amorphous form thereof is provided, having a purity of at least 99.5% and diastereomeric impurity less than 0.25%.
  • a cyclohexyl ammonium salt of Formula I (wherein R ⁇ and R 2 are hydrogen and R is cyclohexyl group) is provided.
  • the cyclohexyl ammonium salt of Fo ⁇ nula I has the X-ray diffraction pattern (XRD) as provided in Figure 1.
  • a diisopropyl ammonium salt of Formula I (wherein R ⁇ and R 2 are isopropyl groups and R 3 is hydrogen) is provided.
  • the diisopropyl ammonium salt of Fo ⁇ nula I has the X-ray diffraction pattern (XRD) as provided in Figure 2.
  • an isopropyl ammonium salt of Formula I (wherein R ⁇ and R 2 are hydrogen and R 3 is isopropyl) is provided.
  • the isopropyl ammonium salt of Formula I has the X-ray diffraction pattern (XRD) as provided in Figure 3.
  • a dicyclohexyl ammonium salt of Formula I (wherein Ri and R are cyclohexyl groups and R 3 is hydrogen) is provided.
  • the dicyclohexyl ammonium salt of Formula I has the X-ray diffraction pattern (XRD) as provided in Figure 4.
  • an (S) (+)- G-methylbenzyl ammonium salt of Formula I (wherein R ⁇ and R 2 are hydrogen and R 3 is (S) (+)- D-methylbenzyl group) is provided.
  • the (S) (+)- D-methylbenzyl ammonium salt of Formula I has the X-ray diffraction pattern (XRD) as provided in Figure 5.
  • pharmaceutical compositions comprising amine salts of rosuvastatin of Formula I with a pharmaceutically acceptable diluent or carrier are provided.
  • a method of treating disease conditions wherein HMG-CoA is implicated comprises of administering to a mammal in need thereof a therapeutically effective amount of amine salt of rosuvastatin of Formula I.
  • Example 1 Preparation of Rosuvastatin Cyclohexyl Ammonium Salt Rosuvastatin acid (2.0 g) was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C. To the solution was added cyclohexylamine and the resultant mass was strrred for 30 minutes at about 0°C. The precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.6 g) with HPLC purity: 98.78%, and diastereomeric impurity 0.51%. The compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%. XRD is as per Figure 1.
  • Example 2 Preparation of Rosuvastatin Diisopropyl Ammonium Salt
  • Rosuvastatin acid 2.0 g was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C.
  • diisopropylamine To the solution was added diisopropylamine and the resultant mass was stirred for 30 minutes at about 0°C.
  • the precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.8 g) with HPLC purity: 98.6%, and diastereomeric impurity 0.52%>.
  • the compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%.
  • XRD is as per Figure 2.
  • Example 3 Preparation of Rosuvastatin Isopropyl Ammonium Salt
  • Rosuvastatin acid 2.0 g was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C.
  • isopropylamine To the solution was added isopropylamine and the resultant mass was stirred for 30 minutes at about 0°C.
  • the precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.6 g), with HPLC purity: 98.4%, and diastereomeric impurity 0.5%.
  • the compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%.
  • XRD is as per Figure 3.
  • Rosuvastatin acid (2.0 g) was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C. To the solution was added (s)-(+)- D-methylbenzyl amine and the resultant mass was stirred for 30 minutes at about 0°C. The precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.7 g), with HPLC purity: 98.2%, and diastereomeric impurity 0.54%. The compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%. XRD is as per Figure 5.
  • Step a) Preparation of rosuvastatin lactone from rosuvastatin diisopropyl ammonium salt.
  • Rosuvastatin diisopropyl ammonium salt (2 gm) was added into mixture of ethyl acetate (10 ml) and water (20 ml) at 25-30°C and the pH of the reaction mass was adjusted to about 3.0 with 6N hydrochloric acid. The layers were separated and the organic layer is washed with water (5 ml). The organic layer was concentrated under vacuum to get an oily crude product, which was mixed with toluene (5 ml). The reaction mass was refluxed for about 6 hours and the solvent was removed under vacuum at 60°C. The residue obtained was stirred with hexane (10 ml) and the separated solid was filtered. Dried the product under vacuum till constant weight at 40-45°C to get rosuvastatin lactone.
  • Step b) Conversion of rosuvastatin lactone to amorphous rosuvastatin calcium.
  • Rosuvastatin lactone as obtained in step a) of Example 6 was dissolved in methanol (10 ml) and water (10 ml). To this solution was added, 8% sodium hydroxide solution until the pH of the reaction mass was about 8.5 to 8.7 and stirred for further 3 hours. After ensuring the absence of rosuvastatin lactone by TLC, solvent was removed under vacuum and the aqueous layer was washed with methyl tert-butyl ether (8 ml).
  • Step c) Conversion of amorphous rosuvastatin calcium to crystalline rosuvastatin calcium
  • Amorphous rosuvastatin calcium (1.0 gm) was added to a mixture of water (5 ml) and acetonitrile (5 ml) at 15°C. The mixture was warmed to 40°C to obtain complete solution. The mixture was then cooled slowly to 25-30°C and stirred for 16 hours. The crystalline product was separated by filtration at ambient temperature and dried at 50°C under vacuum to give rosuvastatin calcium as white crystals, in a yield of 0.68 gm (68%) (XRD as per Figure 7 showed it to be crystalline material).
  • Example 7 Preparation of Crystalline Rosuvastatin Magnesium from Rosuvastatin Diisopropyl Ammonium Salt
  • Rosuvastatin diisopropyl ammonium salt (1.0 g) was added into mixture of ethyl acetate (50 ml) and water (10 ml) and the pH of the reaction mass adjusted to about 3 with hydrochloric acid (6N). The layers were separated and the organic layer is washed with water (3 ml).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to salts of HMG CoA reductase inhibitors, and in particular, rosuvastatin amine salts and their use as intermediates in the preparation of rosuvastatin calcium.

Description

SALTS OF HMG-CoA REDUCTASE INHIBITORS AND USE THEREOF Field of Invention The present invention relates to salts of HMG CoA reductase inhibitors^ and in particular, rosuvastatin amine salts and their use as intermediates in the preparation of rosuvastatin calcium. Background of the Invention Rosuvastatin is (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(l-methylethyl)-2-[methyl (methylsulfonyl)amino]-5-ρyrimidinyl]-3,5-dihydroxy-6-heptenoic acid, shown as Formula II below, wherein R is a hydrogen atom. Rosuvastatin or its pharmaceutically acceptable salts, such as rosuvastatin calcium of Formula Ila (wherein R is calcium) and rosuvastatin magnesium of Formula lib (wherein R is magnesium) are antihypercholesterolemic drugs used in the treatment of atherosclerosis.
A
FORMULA B FORMULA II FORMULA Ila FORMULA lib
U.S. Patent No. RE 37,314 describes a process for the preparation of amorphous rosuvastatin calcium by dissolving the corresponding sodium salt in water, adding calcium chloride and collecting the resultant precipitate by filtration. U.S. Patent No. 6,589,959 describes a process for the preparation of crystalline Form A of rosuvastatm by warming amorphous rosuvastatin calcium in a mixture of water and acetonitrile, cooling the resultant solution to ambient temperature, and then filtering the product which is then dried at 50°C under vacuum to give crystalline Form A of rosuvastatin calcium. PCT patent application WO 01/60804 describes the preparation of crystalline rosuvastatin salts, namely, ammonium, methylammonium, ethylammonium, diethanolammonium, tri(hydroxymethyl)-methylammonium, benzylammonium, 4-methoxybenzylammonium, lithium and magnesium salts of crystalline rosuvastatin. A process for preparation of rosuvastatin calcium from all these salts is also described in this patent application. With the advent of worldwide pharmaceutical regulations, and increased emphasis on drug product quality, it is very important for pharmaceutical companies to produce drug substances having higher purity and lower impurity content. Summary of the Invention Amine salts of rosuvastatin of Formula I are provided herein,
FORMULA I
which can be useful as intermediates in the preparation of pharmacologically acceptable salts of rosuvastatin, such as rosuvastatin calcium or rosuvastatin magnesium. Also provided herein are processes for the preparation of amine salts of rosuvastatin. Also provided herein are processes of converting amine salts of rosuvastatin to phaπnaceutically acceptable salts of rosuvastatin, such as calcium or magnesium. Also provided herein are pharmaceutical compositions comprising amine salts of rosuvastatin along with pharmaceutically acceptable excipients and/or carriers and methods of treatment of disease in which HMG-CoA reductase is implicated. While developing commercially viable processes for the production of rosuvastatin or its pharmaceutically acceptable salt, a significant challenge to process chemists is how to achieve desired high purity and minimize the impurity content. It is now found that particular amine salts of rosuvastatin can be obtained in pure form from rosuvastatin lactone or from rosuvastatin acid, and which can then be used as intermediates in preparation of rosuvastatin or pharmaceutically acceptable salts and the lactone thereof. The term "amine salts" of rosuvastatin of Formula I refers to an amine salt or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula NRiR R wherein independently R1; R2 and R3 are H, straight or branched chain C S alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently R ? R2 and R3 can combine with each other to form a C3.7 membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms (selected from S, N or O), with the proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4- methoxybenzylamine. The term "rosuvastatin of Formula II" refers to the free acid of rosuvastatin, wherein R" is of Formula A and R is hydrogen or lactone form of compound of Formula II wherein R" is of Formula B. The term also encompasses salts wherein R in Formula A is selected from metal ions capable of forming a salt or an amino acid residue and esters of rosuvastatin wherein R in Formula A is selected from optionally substituted -5 alkyl, aryl, cycloalkyl and heterocyclic residues. The term also covers compounds of Formula II which can be present in crystalline, solvate, hydrate or amorphous form thereof. Detailed Description of the Drawings Figure 1 is an X-ray diffraction pattern of the cyclohexyl ammonium salt of rosuvastatin, as prepared in Example 1. Figure 2 is an X-ray diffraction pattern of the diisopropyl ammonium salt of rosuvastatin, as prepared in Example 2. Figure 3 is an X-ray diffraction pattern of the isopropyl ammonium salt of rosuvastatin, as prepared in Example 3. Figure 4 is an X-ray diffraction pattern of the dicyclohexyl ammonium salt of rosuvastatin, as prepared in Example 4. Figure 5 is an X-ray diffraction pattern of the (S) (+)- D-methylbenzyl ammonium salt of rosuvastatm, as prepared in Example 5. Figure 6 is an X-ray diffraction pattern of amorphous rosuvastatin calcium, as prepared in Example 6, step b). Figure 7 is an X-ray diffraction pattern of crystalline rosuvastatin calcium, as prepared in Example 6, step c). Figure 8 is an X-ray diffraction pattern of crystalline rosuvastatin magnesium, as prepared in Example 7. Detailed Description of the Invention In one aspect, amine salts of rosuvastatin of Formula I or solvate, hydrate, crystalline or amorphous forms thereof are provided, in which the amine residue has the formula NRiR R3 wherein independently R1} R2 and R3 are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyL alkylcycloalkyl, or independently Rl5 R2 and R3 can combine with each other to form a C3.7 membered cycloalkyl ring or heterocyclic residue, containing one or more heteroatoms (S, N or O), with the proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4- methoxybenzylamine. In another aspect, amine salts of rosuvastatin of Formula I having purity above 99% and diastereomeric impurity less than 0.5%, are also provided, for example, with purity more than 99.5% and diastereomeric impurity less than 0.25%, or with purity more than 99.75% and diastereomeric impurity less than 0.15%. In another aspect, a process for preparation of amine salts of rosuvastatin of Formula I is provided. The process comprises: a) treating rosuvastatin of Formula II with an amine of Formula NR1R2R3 wherein independently Rl5 R2 and R3 are H, straight or branched chain C S alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl or independently Rl5 R2 and R3 can combine with each other to form a C3.7 membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms, with the proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4- methoxybenzylamine; and b) isolating the amine salt of rosuvastatin of Formula I. Rosuvastatin of Formula II can be dissolved or suspended in an organic solvent and to this mass can be added an amine of Formula NRιR2R3 wherein Rl5 R2 and R3 are as defined above at a temperature of from about -50 to about 100°C. Amine salts of rosuvastatin of Formula I can precipitate from the reaction mass after stirring, which is then isolated, for example, by filtration. The product can optionally be washed with a second organic solvent, in which compounds of Formula I are insoluble or very slightly soluble or sparingly soluble. The product can then suitably be dried to get amine salts of rosuvastatin of Formula I in pure form, which can be further purified by crystallization or any other suitable method such as column chromatography. The organic solvent used in the reaction is characterized by the fact that rosuvastatin of Formula II is very soluble or soluble in it whereas amine salts of rosuvastatin of Formula I are slightly soluble, very slightly soluble or insoluble in such solvent. Some examples of such organic solvents are: esters such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate and isobutyl acetate; ketones such as acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone; and chlorinated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride and ethylene dichloride. The second organic solvent (in which amine salts of rosuvastatin of Formula I are insoluble (10,000 and over parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) or very slightly soluble (form 1,000 to 10,000 parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) or sparingly soluble (from 30 to 100 parts of solvent required for 1 part of solute as per United States Pharmacopoeia 2002) can be, for example, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane, diethyl ether, diisopropyl ether or mixtures thereof. hi another aspect, amine salts of rosuvastatin of Formula I or solvate, hydrate, crystalline or amorphous form thereof are provided, in which the amine residue has a Formula NRtRaRa (wherein independently Rl5 R and R3 are H, straight or branched chain Cι-15 alkyl or hydroxyalkyl, C3-10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently Rls R2 and R3 can combine with each other to form a C3.7 membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms, with the proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4- methoxybenzylamine). These salts can be provided as intermediates for the preparation of rosuvastatin or pharmaceutically acceptable salts, esters and lactones thereof. Processes provided herein for the preparation of amine salts of rosuvastatin of
Formula I are straightforward and simpler, as compared to processes described in, for example, PCT application WO 01/60804, with respect to the number and quantity of solvents used, reaction time and temperature, purity of product obtained and ease of isolating the final product. The amine salts of Formula I as prepared by processes provided herein can be isolated as crystalline solids having a purity of at least above
99.0% and diastereomeric impurity less than 0.5%. These amine salts of Formula I can be easily purified further by simple crystallization technique without significant loss during purification to achieve a purity of above 99.75% and diastereomeric impurity less than 0.5%. Thus, their use as intermediates is substantiated in preparation of rosuvastatin or pharmaceutically acceptable salts, esters and lactone thereof, which are commercially used as drug substances. In another aspect, processes for the preparation of amorphous or crystalline rosuvastatin calcium of Formula Ila from amine salt of Formula I are provided herein, wherein the process comprises: a) treating an amine salt of a compound of Formula I with an acid; b) optionally isolating rosuvastatm acid or a lactone thereof; c) adding a base and calcium ions; d) isolating amorphous rosuvastatin calcium; and e) optionally converting amorphous rosuvastatin calcium to crystalline rosuvastatin calcium. Rosuvastatin amine salt of Formula I can be treated with an acid, at a pH of about 1 to about 4, to get rosuvastatin lactone, or at pH of about 4.5 to about 5, to get rosuvastatin acid. The reaction can be carried out in the presence of a first organic solvent, optionally containing water, at a temperature of from about -10 to about 100°C. After completion of the reaction, the layers are separated and organic layer after washing with water and/or brine is concentrated completely under vacuum. The residue obtained when the reaction pH is adjusted between 4.5 to 5 gives rosuvastatin acid as an oily liquid, which can then be dissolved in water and a first organic solvent, and treated with a base and calcium ions to give rosuvastatin calcium, which precipitates from the reaction mass as amorphous solid. In order to prepare rosuvastatin lactone, the mixture can be stirred at a temperature of about 40 to about 150°C for about 1 to about 50 hours to effect lactonization. After completion of lactonization, the second organic solvent can be removed from the reaction mass, for example, under vacuum, and the residue can be treated with second organic solvent to get the rosuvastatin lactone. The residue can be as such taken in the next step without actually isolating the lactone. The acid can be, for example, an inorganic mineral acid such as hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid; or an organic acid such as formic acid, acetic acid and the like. The first organic solvent can be, for example, lower alkanols, ethers, esters, ketones, polar aprotic solvents, alkyl, aromatic or cycloalkyl hydrocarbons or mixtures thereof. The lower alkanol can be, for example, methanol, ethanol, isopropanol, isobutanol, n-butanol and n-propanol. The ethers can be, for example, tetrahydrofuran, 1,4-dioxane, diethyl ether and diisopropyl ether. The esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and amyl acetate. The ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone. Polar aprotic solvents can be, for example, N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N-methylpyrrolidone. Alkyl, aromatic or cycloalkyl hydrocarbons can be, for example, toluene, benzene, xylene, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane or mixtures thereof. The second organic solvent (characterized by the fact that rosuvastatin is insoluble or very slightly soluble or sparingly soluble in it) can be, for example, isopropanol, isobutanol, n-butanol, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane, diethyl ether, diisopropyl ether or mixtures thereof. The lactone can then be dissolved in an organic solvent, optionally containing water, and treated with a base at a temperature of about 10 to about 70°C for about 1 to about 40 hours to effect hydrolysis of the lactone. The reaction mass pH during the reaction can be adjusted to within the range of about 7.5 to about 11 using a base. The solvent can then be removed and the residue can be taken up in water. The aqueous solution can be washed with the first organic solvent as described earlier, and then treated with calcium ions, after which rosuvastatm calcium can precipitate from the aqueous solution as the amorphous solid. The base can be, for example, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate or potassium bicarbonate. The calcium ions can be generated by using a calcium compound which can be, for example, calcium chloride, calcium hydroxide, calcium carbonate, calcium acetate, calcium sulphate, calcium borate, calcium tartarate, calcium bromide or any other compound capable of generating calcium ions. hi another aspect, a process for the preparation of amorphous rosuvastatin calcium from amine salt rosuvastatm of Formula I is provided. The process comprises: a) treating an amine salt of rosuvastatin with a base and a calcium ions; and b) isolating amorphous rosuvastatin calcium from the reaction mass. Examples of base and calcium ion generating compounds are described in detail above. The conversion can be easily carried out in presence of water, optionally containing an organic solvent. The reaction temperature can be kept at about -5 to about 100°C. The organic solvent can be, for example, lower alkanols, ethers, esters, ketones, polar aprotic solvents, alkyl or cycloalkyl hydrocarbons or mixtures thereof. The lower alkanol can be, for example, methanol, ethanol, isopropanol, isobutanol, n-butanol and n- propanol. The ethers can be, for example, tetrahydrofuran, 1,4-dioxane, diethyl ether and diisopropyl ether. The esters can be, for example, ethyl formate, methyl acetate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, butyl acetate and amyl acetate. The ketones can be, for example, acetone, ethyl methyl ketone, methyl isobutyl ketone and diisobutyl ketone. Polar aprotic solvents can be, for example, N,N- dimethylformamide, N,N-dimethylacetamide, dimethylsulphoxide, acetonitrile and N- methylpyrrolidone. Alkyl or cycloalkyl hydrocarbons can be, for example, cyclopentane, cyclohexane, cycloheptane, hexane, petroleum ether, heptane or mixtures thereof. The amorphous rosuvastatin calcium prepared as described above can have a purity of at least 99%, having less than 0.5% of diastereomeric impurity. It can then be crystallized by, for example, methods described in the US Patent No. 6,589,959, to get crystalline rosuvastatin calcium which can be further converted to amorphous rosuvastatin calcium by, for example, methods described in Indian application 1304/DEL/2003. In another aspect, processes for the preparation of amorphous or crystalline rosuvastatin magnesium of Formula lib from amine salt of Formula I are provided. The processes comprise: a) treating an amine salt of a compound of Formula I with an acid; b) optionally isolating rosuvastatin acid or a lactone thereof; c) adding a base and magnesium ions; d) isolating crystalline rosuvastatin magnesium; and e) optionally converting crystalline rosuvastatin magnesium to amorphous rosuvastatin magnesium. The process is similar to that described earlier, however magnesium ions are used to prepare rosuvastatin magnesium instead of calcium ions. The product obtained is crystalline rosuvastatin magnesium unlike the amorphous form obtained in case of rosuvastatin calcium. The magnesium ions can be generated by using a magnesium compound such as, for example, magnesium chloride, magnesium hydroxide, magnesium carbonate, magnesium acetate, magnesium sulphate, magnesium borate, magnesium tartarate, magnesium bromide or any other compound capable of generating magnesium ions. In another aspect, processes for the preparation of amorphous rosuvastatin magnesium from amine salt of rosuvastatin of Formula I are provided. The processes comprise: a) treating an amine salt of rosuvastatin with a base and a magnesium ions; and b) isolating the crystalline rosuvastatm magnesium from the reaction mass. The process is similar to that described earlier, however, magnesium ions are used to prepare rosuvastatin magnesium instead of calcium ions. The product obtained is crystalline rosuvastatin magnesium unlike the amorphous form obtained in case of rosuvastatin calcium. The crystalline forms of rosuvastatin magnesium obtained above can be converted to amorphous rosuvastatin magnesium by, for example, processes described in hidian application 1304/DEL/2003. hi another aspect, highly pure rosuvastatin calcium or rosuvastatin magnesium in crystalline or amorphous form thereof is provided, having a purity of at least 99.5% and diastereomeric impurity less than 0.25%. In another aspect, a cyclohexyl ammonium salt of Formula I (wherein R\ and R2 are hydrogen and R is cyclohexyl group) is provided. The cyclohexyl ammonium salt of Foπnula I has the X-ray diffraction pattern (XRD) as provided in Figure 1. hi another aspect, a diisopropyl ammonium salt of Formula I (wherein R\ and R2 are isopropyl groups and R3 is hydrogen) is provided. The diisopropyl ammonium salt of Foπnula I has the X-ray diffraction pattern (XRD) as provided in Figure 2. In another aspect, an isopropyl ammonium salt of Formula I (wherein R\ and R2 are hydrogen and R3 is isopropyl) is provided. The isopropyl ammonium salt of Formula I has the X-ray diffraction pattern (XRD) as provided in Figure 3. In another aspect, a dicyclohexyl ammonium salt of Formula I (wherein Ri and R are cyclohexyl groups and R3 is hydrogen) is provided. The dicyclohexyl ammonium salt of Formula I has the X-ray diffraction pattern (XRD) as provided in Figure 4. In another aspect, an (S) (+)- G-methylbenzyl ammonium salt of Formula I (wherein R\ and R2 are hydrogen and R3 is (S) (+)- D-methylbenzyl group) is provided. The (S) (+)- D-methylbenzyl ammonium salt of Formula I has the X-ray diffraction pattern (XRD) as provided in Figure 5. In another aspect, pharmaceutical compositions comprising amine salts of rosuvastatin of Formula I with a pharmaceutically acceptable diluent or carrier are provided. In another aspect, a method of treating disease conditions wherein HMG-CoA is implicated is provided, which comprises of administering to a mammal in need thereof a therapeutically effective amount of amine salt of rosuvastatin of Formula I. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention. EXAMPLES
Example 1: Preparation of Rosuvastatin Cyclohexyl Ammonium Salt Rosuvastatin acid (2.0 g) was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C. To the solution was added cyclohexylamine and the resultant mass was strrred for 30 minutes at about 0°C. The precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.6 g) with HPLC purity: 98.78%, and diastereomeric impurity 0.51%. The compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%. XRD is as per Figure 1.
Example 2: Preparation of Rosuvastatin Diisopropyl Ammonium Salt Rosuvastatin acid (2.0 g) was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C. To the solution was added diisopropylamine and the resultant mass was stirred for 30 minutes at about 0°C. The precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.8 g) with HPLC purity: 98.6%, and diastereomeric impurity 0.52%>. The compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%. XRD is as per Figure 2.
Example 3: Preparation of Rosuvastatin Isopropyl Ammonium Salt Rosuvastatin acid (2.0 g) was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C. To the solution was added isopropylamine and the resultant mass was stirred for 30 minutes at about 0°C. The precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.6 g), with HPLC purity: 98.4%, and diastereomeric impurity 0.5%. The compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%. XRD is as per Figure 3.
Example 4: Preparation of Rosuvastatin Dicyclohexyl Ammonium Salt
Rosuvastatin acid (2.0 g) was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C. To the solution was added dicyclohexylamine and the resultant mass was stirred for 30 minutes at about 0°C. The precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.9 g), with HPLC purity: 98.8%, and diastereomeric impurity 0.49%. The compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%. XRD is as per Figure 4. Example 5: Preparation of Rosuvastatin (S)-(+ -D-Methylbenzyl Ammonium Salt
Rosuvastatin acid (2.0 g) was dissolved in ethyl acetate (10 ml) and the solution was cooled to about 0°C. To the solution was added (s)-(+)- D-methylbenzyl amine and the resultant mass was stirred for 30 minutes at about 0°C. The precipitated solid compound was filtered and washed with hexane and dried under vacuum at 45°C to give title compound (1.7 g), with HPLC purity: 98.2%, and diastereomeric impurity 0.54%. The compound was further recrystallized from ethyl acetate to obtain pure title compound having purity above 99.5% and diastereomeric impurity less than 0.25%. XRD is as per Figure 5.
Example 6: Preparation of Rosuvastatin Calcium from Diisopropyl Ammonium Salt of Rosuvastatin
Step a) Preparation of rosuvastatin lactone from rosuvastatin diisopropyl ammonium salt. Rosuvastatin diisopropyl ammonium salt (2 gm) was added into mixture of ethyl acetate (10 ml) and water (20 ml) at 25-30°C and the pH of the reaction mass was adjusted to about 3.0 with 6N hydrochloric acid. The layers were separated and the organic layer is washed with water (5 ml). The organic layer was concentrated under vacuum to get an oily crude product, which was mixed with toluene (5 ml). The reaction mass was refluxed for about 6 hours and the solvent was removed under vacuum at 60°C. The residue obtained was stirred with hexane (10 ml) and the separated solid was filtered. Dried the product under vacuum till constant weight at 40-45°C to get rosuvastatin lactone.
Step b) Conversion of rosuvastatin lactone to amorphous rosuvastatin calcium. Rosuvastatin lactone as obtained in step a) of Example 6 was dissolved in methanol (10 ml) and water (10 ml). To this solution was added, 8% sodium hydroxide solution until the pH of the reaction mass was about 8.5 to 8.7 and stirred for further 3 hours. After ensuring the absence of rosuvastatin lactone by TLC, solvent was removed under vacuum and the aqueous layer was washed with methyl tert-butyl ether (8 ml). The traces of methyl tert-butyl ether were removed under vacuum and to the aqueous layer added a solution of calcium chloride dihydrate (0.45 gm) in water (2.5 ml) at 20-22°C with vigorous stirring. After complete addition, mixture was stirred for further 2 hours at 20- 22°C and filtered, washed the cake with water (2 ml) thrice and then dried at 45°C under vacuum to get amorphous rosuvastatin calcium. The yield was 1.53 gm (83%) (XRD as per Figure 6 showed it to be an amorphous material). Step c) Conversion of amorphous rosuvastatin calcium to crystalline rosuvastatin calcium Amorphous rosuvastatin calcium (1.0 gm) was added to a mixture of water (5 ml) and acetonitrile (5 ml) at 15°C. The mixture was warmed to 40°C to obtain complete solution. The mixture was then cooled slowly to 25-30°C and stirred for 16 hours. The crystalline product was separated by filtration at ambient temperature and dried at 50°C under vacuum to give rosuvastatin calcium as white crystals, in a yield of 0.68 gm (68%) (XRD as per Figure 7 showed it to be crystalline material).
Example 7: Preparation of Crystalline Rosuvastatin Magnesium from Rosuvastatin Diisopropyl Ammonium Salt Rosuvastatin diisopropyl ammonium salt (1.0 g) was added into mixture of ethyl acetate (50 ml) and water (10 ml) and the pH of the reaction mass adjusted to about 3 with hydrochloric acid (6N). The layers were separated and the organic layer is washed with water (3 ml). The organic layer was concentrated under vacuum at 40°C to get oily crude residue which was dissolved in methanol (5 ml) and water (5 ml) and charged a solution of aqueous sodium hydroxide (0.9 ml, 8% w/v) at 25-30°C and stirred for further 30 min. Methanol was removed under vacuum at 40°C. To the resultant aqueous solution was added a solution of magnesium diacetate tetrahydrate (0.25 g, 20% in water) at 35°C under vigorous agitation. The resultant mass was further stirred for 1 hour at RT and solid crystalline product was collected by filtration. The product was dried under vacuum at 50°C, with a yield: 0.8 g (80%) (XRD as per Figure 8 showed it to be crystalline material)

Claims

We Claim: Amine salts of rosuvastatin of Formula I
or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula NRiR2R3 (wherein independently Rl5 R and R3 are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently Rls R2 and R combine with each other to form a C - membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms), with the proviso that amine is not ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)- methylamine, benzylamine, or 4-methoxybenzylamine.
2. The amine salts of rosuvastatm of claim 1, having purity above 99% and diastereomeric impurity less than 0.5%.
3. The compound according to claim 2, wherein the purity is more than 99.5% and diastereomeric impurity less than 0.25%.
4. The compound according to claim 3, wherein the purity is more than 99.75% and diastereomeric impurity less than 0.15%.
5. A process for the preparation of amine salts of rosuvastatin of Formula I
or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula NR1R2R3 (wherein independently R\, R2 and R3 are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently Ri, R2 and R3 combine with each other to form a C3.7 membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms), with the proviso that amine is not ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)- methylamine, benzylamine, or 4-methoxybenzylamine, the process comprising: a) treating rosuvastatin of Formula II
A
FORMULA B with an amine of Formula NR^2R3 (wherein independently Rj, R2 and R3 are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently R1? R2 and R3 combine with each other to form a C3. membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms), with a proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4-methoxybenzylamine; and b) isolating the amine salt of rosuvastatin of Formula I. Amine salts of rosuvastatin of Formula I
or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula NRiR2R3 (wherein independently Rl5 R2 and R3 are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently R1} R2 and R3 combine with each other to form a C3. membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms), with a proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4-methoxybenzylamine as intermediates for the preparation of rosuvastatin or pharmaceutically acceptable salts, esters and lactones thereof.
7. A process for preparation of amorphous or crystalline rosuvastatin calcium of Formula Ila from amine salt of Formula I,
A
FORMULA B
wherein the process comprises of a) treating an amine salt of Formula I,
or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Foπnula NRιR2R3 (wherein independently Rl5 R2 and R3 are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently Rls R2 and R3 combine with each other to form a C3. 7 membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms), with a proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4-methoxybenzylamine, with an acid; b) optionally isolating rosuvastatin acid or a lactone thereof; c) adding a base and calcium ions; d) isolating amorphous rosuvastatin calcium; and e) optionally converting amorphous rosuvastatin calcium to crystalline rosuvastatin calcium.
8. A process for the preparation of amorphous rosuvastatin calcium from amine salt rosuvastatin of Formula I
or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula (wherein independently Rls R2 and R are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently Ri, R2 and R3 combine with each other to form a C -7 membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms), with a proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymemyl)-methylamine, benzylamine, or 4-methoxybenzylamine, the process comprising a) treating an amine salt of rosuvastatin with a base and a calcium ions; and b) isolating the amorphous rosuvastatin calcium from the reaction mass.
9. Amorphous rosuvastatin calcium prepared by a process according to claims 7 and 8 having a purity of at least above 99% having less than 0.5% of diastereomeric impurity.
10. A process for preparation of amorphous or crystalline rosuvastatin magnesium of
A
Formula lib FORMULA B from amine salt of Formula I,
or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula NRiR2R3 (wherein independently Rls R2 and R3 are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently Rls R2 and R combine with each other to form a C3.7 membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms), with a proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4-methoxybenzylamine, wherein the process comprises: a) treating an amine salt of Formula I with an acid; b) optionally isolating rosuvastatin acid or a lactone thereof; c) adding a base and magnesium ions; d) isolating crystalline rosuvastatin magnesium; and e) optionally converting crystalline rosuvastatin magnesium to amorphous rosuvastatin magnesium.
11. A process according to claim 10 wherein the acid is selected from inorganic mineral acids or organic acids.
12. A process for the preparation of amorphous rosuvastatin magnesium from amine salt of rosuvastatin of Formula I
or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula NR1R2R3 (wherein independently Rls R2 and R3 are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3.10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently Rls R2 and R3 combine with each other to form a C3.7 membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms), with a proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4-methoxybenzylamine, which comprises: a) treating an amine salt of rosuvastatin with a base and a magnesium ions; and b) isolating the crystalline rosuvastatin magnesium from the reaction mass.
13. Highly pure rosuvastatin calcium or rosuvastatin magnesium in crystalline or amorphous form thereof having purity of at least above 99.5% and diastereomeric impurity less than 0.25%.
14. A cyclohexyl ammonium salt of Formula I
wherein R1 and R2 are hydrogen and R3 is cyclohexyl group.
15. The cyclohexyl ammonium salt of claim 14, having the X-ray diffraction pattern (XRD) as provided in Figure 1.
16. A diisopropyl ammonium salt of Formula
I wherein Rγ and R2 are isopropyl groups and R3 is hydrogen.
17. The diisopropyl ammonium salt of claim 16 having the X-ray diffraction pattern (XRD) as provided in Figure 2.
18. An isopropyl ammonium salt of Formula I
wherein R\ and R2 are hydrogen and R3 is isopropyl.
19. The isopropyl ammonium salt of claim 18, having the X-ray diffraction pattern (XRD) as provided in Figure 3.
20. A dicyclohexyl ammonium salt of Formula I
wherein R\ and R2 are cyclohexyl groups and R3 is hydrogen.
21. The dicyclohexyl ammonium salt of claim 20, having the X-ray diffraction pattern (XRD) as provided in Figure 4.
22. A (S) (+)- D-methylbenzyl ammonium salt of Formula I
wherein R\ and R2 are hydrogen and R3 is (S) (+)- D-methylbenzyl group.
23. The (S) (+)- D-methylbenzyl ammonium salt of claim 22, having the X-ray diffraction pattern (XRD) as provided in Figure 5.
24. A pharmaceutical composition comprising amine salts of rosuvastatin of Formula I
or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula NRiR2R3 (wherein independently Rl5 R2 and R3 are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3_io single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently Rl3 R2 and R combine with each other to form a C3.7 membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms), with a proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4-methoxybenzylamine, with a pharmaceutically acceptable diluent or carrier.
25. A method of treating disease conditions wherein HMG-CoA is implicated, which comprises of administering to a mammal in need thereof a therapeutically effective amount of amine salt of rosuvastatin of Formula I
or solvate, hydrate, crystalline or amorphous form thereof, in which the amine residue has a Formula NRiR2R3 (wherein independently R\, R2 and R3 are H, straight or branched chain CMS alkyl or hydroxyalkyl, C3-10 single or fused ring optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, alkylcycloalkyl, or independently R\, R2 and R3 combine with each other to form a C3. membered cycloalkyl ring or heterocyclic residue containing one or more heteroatoms), with a proviso that the amine is not selected from ammonia, methylamine, ethylamine, diethanolamine, tri(hydroxymethyl)-methylamine, benzylamine, or 4-methoxybenzylamine.
EP05702276A 2004-01-19 2005-01-19 Salts of hmg-coa reductase inhibitors and use thereof Ceased EP1709008A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN78DE2004 2004-01-19
PCT/IB2005/000114 WO2005077916A1 (en) 2004-01-19 2005-01-19 Salts of hmg-coa reductase inhibitors and use thereof

Publications (1)

Publication Number Publication Date
EP1709008A1 true EP1709008A1 (en) 2006-10-11

Family

ID=34856862

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05702276A Ceased EP1709008A1 (en) 2004-01-19 2005-01-19 Salts of hmg-coa reductase inhibitors and use thereof

Country Status (2)

Country Link
EP (1) EP1709008A1 (en)
WO (1) WO2005077916A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US7932387B2 (en) 2005-01-31 2011-04-26 Basf Se Crystalline forms of rosuvastatin calcium salt
WO2006091771A2 (en) 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
CN101208307B (en) * 2005-06-24 2012-10-17 力奇制药公司 Process for preparing amorphous rosuvastatin calcium free of impurities
CN101330919B (en) * 2005-12-20 2012-12-05 力奇制药公司 Pharmaceutical composition including (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrim idin-5-yl]-(3R, 5S)-3,5-dihydroxyhept-6-enoic acid
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
WO2008015563A2 (en) * 2006-08-04 2008-02-07 Glenmark Pharmaceuticals Limited Salts of rosuvastatin and processes for their preparation
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
EP2086945B1 (en) 2006-10-09 2016-01-06 MSN Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
CN101570510B (en) * 2008-04-30 2011-08-31 上海医药工业研究院 Quinoline compound, pharmaceutical composition, preparation method and application thereof
WO2010035284A2 (en) * 2008-09-26 2010-04-01 Matrix Laboratories Ltd An improved process for the preparation of rosuvastatin calcium
SI2387566T1 (en) * 2009-01-14 2014-07-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of rosuvastatin
EA021942B1 (en) 2009-01-15 2015-10-30 Эгиш Дьёдьсердьяр Зрт. Process for the preparation of rosuvastatin salts
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd Improved process for the preparation of highly pure (3r,5s)-7-ý2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl¨-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
AU2011243948B2 (en) 2010-04-23 2014-07-17 Sun Pharmaceutical Industries Limited Novel intermediates for the preparation of HMG-CoA reductase inhibitors
WO2012063115A2 (en) 2010-11-11 2012-05-18 Jubilant Life Sciences Ltd. Process for the preparation of rosuvastatin calcium via novel amine intermediate
HU230987B1 (en) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Process for the preparation of pharmaceutical intermediates with high purity
HU229260B1 (en) 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
WO2012176218A1 (en) * 2011-06-24 2012-12-27 Ind-Swift Laboratories Limited Process for preparing rosuvastatin calcium through novel amine salt
US9676729B2 (en) 2013-03-29 2017-06-13 Dsm Sinochem Pharmaceuticals Netherlands B.V. Amine salts of pitavastatin and rosuvastatin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3528186B2 (en) * 1991-06-24 2004-05-17 日産化学工業株式会社 Diastereomeric salts of optically active quinoline mevalonic acid
DE69616808T2 (en) * 1995-07-17 2002-05-29 Warner Lambert Co CRYSTALLINES (R- (R *, R *)) - 2- (4-FLUORPHENYL) BETA, DELTA-DIHYDROXY-5- (1-METHYLETHYL) -3-PHENYL-4 - ((PHENYLAMINO) CARBONYL) -1H- PYRROL-1-HEPTANIC CARBONIC ACID HEMI CALCIUM SALT (ATORVASTATIN)
SI20070A (en) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. NOVEL SALTS OF INHIBITORS OF HMG-CoA REDUCTASE
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005077916A1 *

Also Published As

Publication number Publication date
WO2005077916A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
US20090036680A1 (en) Salts of hmg-coa reductase inhibitors and use thereof
EP1709008A1 (en) Salts of hmg-coa reductase inhibitors and use thereof
AU2008355336B2 (en) Crystalline form of tenofovir disoproxil and a process for its preparation
JP2008044948A (en) Process for manufacturing calcium salt of rosuvastatin(e)-7-[4-(4-fluorophenyl)-6-iosopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6-enoic acid and crystalline intermediate thereof
US20070191318A1 (en) Process for the preparation of amorphous rosuvastatin calcium
BRPI0410922B1 (en) process for the formation of a compound
EP1797046A2 (en) Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
US9233963B2 (en) Method for preparing meropenem using zinc powder
CA2711043A1 (en) Method of synthesis of bosentan, its polymorphic forms and its salts
AU2007208965B2 (en) A process for manufacturing Rosuvastatin Potassium and crystalline and amorphous forms thereof
EP1879862B1 (en) Magnesium salts of hmg-coa reductase inhibitors
WO2008038132A1 (en) Crystalline diamine salts of rosuvastatin
EP1737828A1 (en) Amorphous magnesium salts of rosuvastatin
WO2012176218A1 (en) Process for preparing rosuvastatin calcium through novel amine salt
JP2013543884A (en) Manufacturing method for high-purity pharmaceutical intermediates
WO2017191539A1 (en) Process for the preparation dl-proline co-crystal of dapagliflozin
US20100069635A1 (en) Rosuvastatin dehydroabietylamine salt
RU2434869C2 (en) Method of producing abacavir
CA2615691C (en) Process for the preparation of crystalline perindopril
CA2903708C (en) A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
HU229260B1 (en) Process for preparation of rosuvastatin salts
KR101304640B1 (en) Novel n-methylbenzylamine salt of rosuvastatin and process for the preparation thereof
EP2419407B1 (en) Improved process for the preparation of fluvastatin and salts thereof
JP5334852B2 (en) Abacavir manufacturing method
CN105073713A (en) Pharmaceutically acceptable amine salts of pitavastatin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060821

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070821

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20101218